Tilray Brands, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLRY research report →
Range $10 – $10
Price Chart
About the company
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America.
- CEO
- Irwin David Simon
- IPO
- 2018
- Employees
- 3,595
- HQ
- Leamington, ON, CA
Get TickerSpark's AI analysis on TLRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $211.36M
- P/E
- -1.61
- Fwd P/E
- 15.12
- PEG
- -0.02
- P/S
- 0.26
- P/B
- 0.18
- EV/EBITDA
- -22.06
- Div Yield
- 0.00%
- Gross Margin
- 28.48%
- Op Margin
- -8.02%
- Net Margin
- -17.05%
- ROE
- -10.30%
- ROIC
- -3.88%
Latest fiscal year · YoY change
- Revenue
- $915.45M+11.5%
- Gross Profit
- $260.44M+8.3%
- Op Income
- $-63,027,000
- Net Income
- $-122,567,000+94.4%
- EPS
- $-1.09+95.6%
- OCF Growth
- +26.9%
- FCF Growth
- +19.9%
- 52W High
- $15.70
- 52W Low
- $1.87
- 50D MA
- $3.24
- 200D MA
- $5.06
- Beta
- 2.05
- RSI (14)
- 23
- Avg Volume
- 4.29M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tilray said its first quarter delivered record revenue and gross profit, with stronger margins and BrewDog helping offset cannabis pricing pressure and U.S. beer weakness, while management reaffirmed fiscal 2027 EBITDA guidance.· October 8, 2026
- Record Q1 revenue was $257.1 million, up 23% year over year, and gross profit rose 35% to $77.5 million with gross margin up about 300 bps to 30%.
- BrewDog was the major beverage driver: beverage revenue rose to $101.5 million, BrewDog added $55.9 million of incremental revenue, and management said BrewDog became profitable in Q1.
- International cannabis remained a key growth engine, with revenue up 21% to $16.2 million and EMEA revenue up over 70% across cannabis, beverage and distribution.
- Tilray reiterated fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million despite industry headwinds, seasonality and integration costs.
- Management emphasized cash discipline, saying it ended the quarter with about $221 million of cash and had retired $24 million of principal in the quarter plus $12 million after quarter-end.
Tilray reported Q1 net revenue of $257.1 million, up 23% from $209.5 million a year ago. Gross profit was $77.5 million, up 35%, and consolidated gross margin improved to 30%, about 300 basis points higher year over year. International cannabis revenue rose 21% to $16.2 million; total cannabis net revenue was $56.1 million versus $64.5 million last year, and cannabis gross margin increased to 39% from 36%. Beverage revenue increased to $101.5 million from $55.7 million, helped by $55.9 million of incremental BrewDog revenue, while CC Pharma distribution revenue rose 14% to $84.3 million. The company reported a net loss of $40 million versus net income of $1.5 million a year ago; adjusted net loss was about $3 million and adjusted EBITDA was $9.2 million versus $10.2 million last year. Looking ahead, management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Irwin Simon framed Tilray as a diversified global platform spanning cannabis, beverage, wellness and pharmaceutical distribution rather than a pure-play cannabis company. His tone was confident and strategic, stressing scale, cost leadership, and the ability to use acquisitions like BrewDog and Carlsberg to build a more profitable, globally recognized business. He repeatedly pointed to optionality from international medical cannabis, U.S. hemp beverages, and future cannabis reform, but said the strategy does not depend on any single regulatory event.
Carl Merton focused on the mechanics behind the quarter’s improvement: revenue grew 23% to $257.1 million, gross profit grew 35% to $77.5 million, and gross margin expanded to 30%. He said cannabis margins improved to 39% from 36% due to operating efficiencies, better mix, and higher utilization at the Portugal facility, while beverage margins improved about 300 bps to 41% thanks to BrewDog. On the balance sheet, he said Tilray ended with about $221 million in cash, restricted cash and marketable securities, retired $24 million of principal in the quarter and another $12 million after quarter-end, and had $52 million of principal outstanding. He also noted BrewDog required no cash injections during the quarter and was self-financing, and he reiterated the $68 million to $75 million fiscal 2027 adjusted EBITDA outlook.
Analysts pressed on international cannabis pricing pressure and competitive consolidation, and Simon answered that Tilray has ample cultivation capacity, established doctor and pharmacy relationships, and CC Pharma’s access to 16,000 drugstores, so he is not concerned about rival combinations. Questions also focused on BrewDog’s quick path to profitability; Simon said the improvement came from avoiding losing bars and pubs, rightsizing staff and leases, closing unprofitable businesses, and benefiting from stronger brand momentum. On Canadian adult-use weakness, he said the softer Q1 reflected seasonal strain rotations and margin-focused decisions, not a permanent change in trajectory. Analysts also asked about Carlsberg and U.S. THC beverages, and management said Carlsberg adds premium brands and potential future expansion opportunities, while Tilray is waiting on regulatory outcomes but is ready to move quickly if hemp drinks or broader U.S. cannabis rules change.
The call’s positive case is that Tilray is showing real margin improvement while scaling a more diversified business. Management highlighted record Q1 revenue and gross profit, BrewDog profitability, international cannabis growth, and a strong cash position, while reaffirming full-year EBITDA guidance despite headwinds. If BrewDog integration, international medical cannabis, and U.S. beverage partnerships keep contributing, the company sees multiple paths to improve earnings power.
The main risks remain cannabis price compression, seasonal volatility, and a U.S. beverage business that would have been down without BrewDog. Management also acknowledged fuel surcharge pressure, higher marketing spend, integration costs, and ongoing uncertainty around cannabis reform and hemp regulation. In Canada and the U.S. beer market, they are still managing competitive pressure, distributor consolidation, and SKU rationalization rather than enjoying broad-based growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 120.1%
- Shares Outstanding
- 111.83M
- Float Shares
- 134.29M
of shares held by institutions
258 13F filers
Buy/sell ratio 0.95. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TLRY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Brian Jeffrey MastHouse · FL18 | — | May 3, 21 | Filing → |
| Brian Jeffrey MastHouse · FL18 | Sell | Feb 9, 21 | Filing → |
| Brian Jeffrey MastHouse · FL18 | Sell | Feb 10, 21 | Filing → |
| John YarmuthHouse · KY03 | Buy | Feb 12, 21 | Filing → |
| Brian Jeffrey MastHouse · FL18 | Buy | Nov 6, 20 | Filing → |
| John YarmuthHouse · KY03 | Buy | Nov 5, 20 | Filing → |
| Brian Jeffrey MastHouse · FL18 | Sell | Feb 4, 19 | Filing → |
| Brian Jeffrey MastHouse · FL18 | Buy | Jan 18, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tidal Investments LLC | 2.72M | ▲ 221.03K |
| Ubs Group AG | 1.25M | ▲ 796.17K |
| Susquehanna International Group, Llp | 1.02M | ▲ 479.55K |
| Morgan Stanley | 935.88K | ▼ 59.27K |
| Citadel Advisors LLC | 868.15K | ▲ 854.24K |
| Point72 Asset Management, L.P. | 648.51K | ▲ 648.51K |
| Mirae Asset Global Etfs Holdings Ltd. | 646.76K | ▲ 159.94K |
| Aqr Capital Management LLC | 512.60K | ▲ 65.01K |
| Vanguard Group Inc | 436.92K | ▼ 3.61M |
| Blackrock, Inc. | 429.92K | ▼ 31.74K |
| Lazard Asset Management LLC | 394.71K | ▲ 394.71K |
| Vanguard Portfolio Management LLC | 378.68K | ▲ 30.00K |
Held by 73 ETFs
Biggest fund positions in TLRY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 26 | SIMON IRWIN D | other | 803,563 |
| Aug 26, 26 | SIMON IRWIN D | other | 425,889 |
| Aug 26, 26 | SIMON IRWIN D | other | 408,605 |
| Aug 26, 26 | SIMON IRWIN D | other | 216,561 |
| Aug 26, 26 | SIMON IRWIN D | other | 803,563 |
| Aug 26, 26 | Merton Carl A | other | 111,072 |
| Aug 26, 26 | Merton Carl A | other | 61,090 |
| Aug 26, 26 | Merton Carl A | other | 57,380 |
| Aug 26, 26 | Merton Carl A | other | 31,559 |
| Aug 26, 26 | Merton Carl A | other | 111,072 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TLRY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on TLRY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Tilray Brands, Inc. (TLRY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
zacks.com · Nov 20
Tilray Brands Board Overhaul Falls Short Despite 77% Support; CEO Targets $30 Million in Savings
marketbeat.com · Nov 20
Tilray Has More Cash Than Debt and 71% Growth in Europe. Is This Cannabis Stock a Buy?
fool.com · Nov 19
Tilray Brands stock has crashed to a record low: is this fallen angel a buy?
invezz.com · Nov 17
Why Didn't Tilray Brands Make a Bid for Aurora Cannabis?
fool.com · Nov 16
Whiskey You Won't Find on Shelves: Breckenridge Distillery Launches the 2 Mile High Whiskey Club
globenewswire.com · Nov 11
Does Marijuana Rescheduling Really Help Tilray's Stock?
fool.com · Nov 10
Tilray Raises Its Guidance for the Year. Is the Stock Finally Headed on the Right Track?
fool.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
